Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Conference News ACC 2026

SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too

Caitlin E. Cox

March 30, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Conference News THT 2026

THT 2026: What to Expect in Boston

Todd Neale

February 23, 2026

News Daily News

Cardioprotective Flush, Without Reanimation, Safe and Effective in DCD Transplant

Michael O'Riordan

January 28, 2026

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

Caitlin E. Cox

August 30, 2025

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

L.A. McKeown

October 02, 2024

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

L.A. McKeown

July 01, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Caitlin E. Cox

April 15, 2024

News Daily News

Aficamten Delivers Positive Results in SEQUOIA-HCM

Todd Neale

December 27, 2023

News Conference News ESC 2023

ESC Cardiomyopathy Guidelines Span Range of Phenotypes

Yael L. Maxwell

August 31, 2023

News Daily News

Top Heart Failure News of 2022

Shelley Wood

January 04, 2023

News Features

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

Shelley Wood

December 20, 2022

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

L.A. McKeown

October 07, 2022

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Daily News

AI-Based Tool IDs Hypertrophic Cardiomyopathy and Cardiac Amyloidosis

Yael L. Maxwell

February 24, 2022

News Daily News

Familial Patterns of Idiopathic Dilated Cardiomyopathy Becoming Clearer

L.A. McKeown

February 10, 2022

News Daily News

Young People With Cardiac Conditions Rarely Die From Sex

Michael O'Riordan

January 18, 2022

Advertisement

SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too

What’s Going to Be Hot at ACC 2026

THT 2026: What to Expect in Boston

Cardioprotective Flush, Without Reanimation, Safe and Effective in DCD Transplant

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

July 2024 Dispatch for the CV Team

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Aficamten Delivers Positive Results in SEQUOIA-HCM

ESC Cardiomyopathy Guidelines Span Range of Phenotypes

Top Heart Failure News of 2022

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

AI-Based Tool IDs Hypertrophic Cardiomyopathy and Cardiac Amyloidosis

Familial Patterns of Idiopathic Dilated Cardiomyopathy Becoming Clearer

Young People With Cardiac Conditions Rarely Die From Sex

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content